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complex with antibacterial treatment, based on the result of microbiological investigation and 
determination of cultural sensitivity highlighted toward antibacterial preparations, also with 
immunomodulator and detoxifying treatment.
Discussion: This case shows the relevant clinical data for treatment of anterior abdominal wall 
phlegmon with cosmetic and minimal economic results.
Conclusions: VAC aspiration system compared to the classical method of suppurative wound 
management has a higher number of advantages, among which are the preservation of prosthetic material 
used in the surgical procedure in particular cases, reducing the frequency of dressing at 48-36 h, which 
is more convenient for patient and lowers treatment costs, the possibility of continuing treatment in 
outpatient system etc. Such activity represents an opportunity for surgeons in surgical service of 
suppuration.
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Introduction: infectious Endocarditis (IE) is a serious disease with incidence of 3-10 to 100.000 
episodes per year, late diagnosis establishing (36-40%), fatal complications: congestive heart failure in 
30%, embolic phenomena in 20%, stroke 15%. Joint manifestations in patients with IE are rare, they are 
manifested by: arthritis-6.4%, sinovitis-2.8% and creates difficulties in establishing early diagnosis.
Clinical Case: Patient Y., 47 years ol d, Diagnosis: Active Infectious Endocarditis with negative 
hemocultures with native valve involvement(aortic valve (AoV), mitral (MV) and the pulmonary artery 
(PA)), MV failure of III degree, AoV II degree, VAp II d egree, HF II NYHA. Chronic Periodontitis.
Chronic hepatitis of viral etiology (HCV), moderate activity.
Results: subfebrility inspiratory dyspnea, palpitations, pain of the mean-severe severity in 
shoulder joint, elbow joint, coxofemural joint, lumbalgias, fatigue. Objective: tegumental peteschias, 
tumefiation of the periarticular regions, rhytmic heart beats, atenuated, BP-135/60 mmHg. FCC-105
b/min. Vesicular murmur in lungs. ECG: Sinusal tachycardia with frequency of 102 beats per minute. 
EAH - horizontal. EcoCG: Moderate dilatation of LA, RV, RA. EF-65%. Plate vegitations, floating on 
the anterior and posterior cusps and MV (7 x 10 mm), floating vegetations of the AoV cusps, MV failure, 
III degree, AoV-II degree, TrV-III degree, ApV-I degree, moderate PHT, PsVD-36 mmHg. General 
blood analysis: anemia (Hb-102 g/l), ESR-40 mm/HR. Biochemical analysis: total bilirubin 25 mmol/l, 
ALT-49.9 mmol/l, AST-66.9 mmol/l, GGT U/l-295.4. General urine analysis: leucocitury, 
immunological tests: Anti-HCV-positive, rheumatoid factor-44 IU/ml, C-reactive protein-384 mg/l. 
Negative hemocultures.
Empirical antimicrobial treatment with sol. Vancomycin -60 mg/kg/day, i/v in 2-3 plugs, Sol. 
Gentamicin-3 mg/kg/day, i/v in a single dose, antifungal, antiinflammatory drugs, diuretics. 
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Conclusions: Patient 47-year-old young man with chronic oral bacteriemia develops IE with 
polyarticular syndrome from the begining, that creates difficulties in early diagnosis establishing and 
lates appropriate antimicrobial treatment.
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Introduction: Angiogenesis (from gr. Angeion blood vessel and genesis - birth) is the process 
of forming new vessels, from the network of existing vessels, the phenomenon begins during fetal life 
and continues in child and adult ensuring growth and development. Aberrations of phenomenon can be 
a condition sin quo non in the pathogenesis of diseases such as cancer. Angiogenesis inhibitors are 
revolutionary products called molecular targeted therapies aimed to inhibiting the progression of 
essential processes in carcinogenesis, one of which is angiogenesis.
Objectives:
1. To evaluate the effectiveness of treatment with bevacizumab in recurrent glioblastoma;
2. To appreciate the tolerability of the product by the patient. Adverse reactions.
Clinical case: Current research is a retrospective analysis of a clinical case, the patient A., 28 
years old, diagnosed with recurrent glioblastoma and treated in Section of Chemotherapy No.2 of the 
Oncological Institute of Chisinau, the patient was monitored from May 2010 to November 2011. The 
evolution of treatment with bevacizumab was monitored using brain MRI executed at optimal intervals.
Results: In the absence of blood vessels who will infiltrate tumor tissue, it cannot exceed 2 mm3
in volume, because oxygen and nutrients can diffuse freely through the tissues just over a distance of 
approx. 200 micrometres, which limits tumor growth and subsequent the metastasis via blood and 
lymphatic vessels. Preventing the activation of tyrosine kinases (TK), angiogenesis inhibitors limit the 
proliferation and migration of cells involved in an angiogenesis process (endoteliocyts, fibroblasts, 
myocytes). The target can be achieved either through monoclonal antibodies wich working as blocking 
ligand-receptor interaction: bevacizumab; trastuzumab, or small molecules that interact directly with the 
intracellular TK acting as competitive inhibitors of ATP binding: imatinib, pazopanib.
Conclusion:
1. For the presented patient the administration of a suitable conservative treatment, then apply a 
contemporary regimen of treatment with Avastin, allowed an increase of survival by 19 months, 
compared with the average statistics for patients with similar staging, but more important is increasing 
the quality of life and reintegration of the patient in the family and society;
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